- ￥7990
- BioporTo
- 丹麦
- ABS 044-53-02
- 2025年07月16日
- human
企业认证
相关产品推荐更多 >
![C18orf34 antibody [N1N2], N-term](https://img1.dxycdn.com/2023/0711/255/2344116916935858761-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 形态：
液体
- 克隆性：
多克隆
- 适应物种：
human
- 抗体英文名：
Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific)
- 抗体名：
Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific)
- 规格：
200µl
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验On Tissue Protein Identification Improvement by N-Terminal Peptide Derivatization
and orients fragmentations toward a specific series of fragment ions. In this respect, N-terminal chemical derivatization has proven to be particularly efficient. N-terminal chemical derivatization of tryptic peptides has been developed to be performed
Backbone Amide Linker Strategy: Protocols for the Synthesis of C-Terminal Peptide Aldehydes
In the backbone amide linker (BAL) strategy, the peptide is anchored not at the C-terminus but through a backbone amide, which leaves the C-terminal available for various modifications. This is thus a very general strategy
Backbone Amide Linker Strategies for the Solid-Phase Synthesis of C - Terminal Modified Peptides
This chapter describes backbone amide linker (BAL) strategies for the N α-Fmoc solid-phase synthesis of C-terminal modified peptides. Most solid-phase protocols for the assembly of such peptides have limited generality, because they rely on the C
技术资料暂无技术资料 索取技术资料
